SHLP-2 Research for Metabolic Syndrome
An evidence-based overview of research examining SHLP-2 in the context of metabolic syndrome. This page synthesizes findings from peer-reviewed literature.
Research Summary
SHLP-2 has been studied for its metabolic regulatory effects in preclinical models. Research demonstrated that SHLP-2 activates CXCR7 receptors in hypothalamic POMC neurons, regulating appetite and energy expenditure (Kim et al., 2023). Mouse studies showed protection against high-fat diet-induced obesity. However, all available evidence is preclinical with no human therapeutic trials.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Metabolic Syndrome
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. SHLP-2 has not received regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.